At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 530 enrolled
Drug / intervention
AZD1656 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 4-month, Randomized, Double-blind, Placebo- and Active-Controlled, Multi-centre, Parallel-Group Study, With an Optional 2-month Extension, to Evaluate Efficacy, Safety and Tolerability of AZD1656 as Add-on Treatment to Metformin in Type 2 Diabetes Mellitus Patients
In Brief
A Phase 2 clinical trial evaluating AZD1656, Placebo, and 1 other intervention for Type II Diabetes Mellitus. Completed, enrolled 530 participants across 77 sites in 11 countries.
Detailed Summary
The primary aim is to evaluate Efficacy, Safety and Tolerability of AZD1656 as Add-on Treatment to Metformin in TD2M Patients
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType II Diabetes Mellitus
CountriesChile, Germany, Hungary, Latvia, Lithuania, Mexico, Peru, Poland, Romania, Sweden, United Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2009
First PostedNov 2009
Primary CompletionFeb 2011
TodayJul 2026
First PostedNov 25, 2009
Enrollment StartOct 1, 2009
Primary CompletionFeb 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 16.6 years ago
Interventions
AZD1656drug
Different doses of AZD1656 administered to 5 groups of patients
Placebodrug
AZD1656 placebo and glipizide placebo administered to 1 group of patients
Glipizidedrug
Glipizide administered to 1 group of patients